Table 3

Baseline characteristics of DISCOVER patients included in the analysis

Total
N=11 385
Asia-Pacific n=5206Europe n=2174Latin America n=1161Middle East and Africa n=2624
Men6387 (56.1)3037 (58.3)1212 (55.7)538 (46.3)1459 (55.6)
Self-reported ethnicity
 Caucasian3004 (27.5)122 (2.3)1839 (94.5)390 (33.7)644 (24.6)
 Black122 (1.1)1 (0.0)7 (0.4)58 (5.0)54 (2.1)
 Asian5269 (48.1)5069 (97.4)15 (0.8)7 (0.6)175 (6.7)
 Hispanic612 (5.6)1 (0.0)7 (0.4)603 (52.1)1 (0.0)
 Arabic1734 (15.8)2 (0.0)7 (0.4)2 (0.2)1722 (65.8)
 Mixed100 (0.9)1 (0.0)3 (0.2)89 (7.7)7 (0.3)
 Other103 (0.9)9 (0.2)68 (3.5)9 (0.8)16 (0.6)
 Missing442122835
Age, mean (SD), years57.4 (12.1)56.5 (12.4)63.1 (10.6)58.5 (11.4)54.1 (10.8)
HbA1c, mean (SD), %8.3 (1.7)8.3 (1.7)8.0 (1.5)8.5 (1.9)8.6 (1.6)
BMI, mean (SD), kg/m229.1 (5.9)26.7 (4.8)31.9 (6.1)30.4 (5.5)31.0 (5.8)
Time since T2D diagnosis, mean (SD), years5.6 (5.2)5.0 (5.0)6.5 (5.3)6.5 (6.1)6.0 (5.2)
Tobacco smoking
 Non-smoker7596 (66.7)3548 (68.1)1281 (58.9)750 (64.6)1878 (71.6)
 Ex-smoker1990 (17.5)808 (15.5)515 (23.7)305 (26.3)329 (12.5)
 Current smoker1799 (15.8)850 (16.3)378 (17.4)106 (9.1)417 (15.9)
Comorbidities*
 Hypertension5899 (51.8)2406 (46.2)1569 (72.2)670 (57.7)1103 (42.0)
 Hyperlipidemia5658 (49.7)2549 (49.0)1344 (61.8)576 (49.6)1032 (39.3)
 CKD634 (5.6)326 (6.3)186 (8.6)48 (4.1)53 (2.0)
 Macrovascular complication(s)†1634 (14.4)512 (9.8)628 (28.9)174 (15.0)289 (11.0)
Use of comedication
 Lipid-lowering drugs5568 (48.9)2459 (47.2)1215 (55.9)579 (49.9)1200 (45.7)
 Antihypertensive drugs5755 (50.5)2297 (44.1)1515 (69.7)666 (57.4)1156 (44.1)
  • Data are reported as n (%) unless otherwise stated. The numbers of patients with missing data are reported for relevant variables; data were available for all patients for all other variables in the table. Percentages were calculated for all patients with data.

  • *Marked as present by the investigator in the electronic case report form.

  • †Composite of coronary heart disease, cerebrovascular disease, peripheral artery disease, heart failure, and implantable cardioverter defibrillator use.

  • BMI, body mass index;CKD, chronic kidney disease;HbA1c,glycated hemoglobin;T2D, type 2 diabetes.